Addictions
Canada’s ‘safer supply’ patients are receiving staggering amounts of narcotics
Image courtesy of Midjourney.
|
|
How a Small Population Fuels a Black Market Epidemic, Echoing Troubling Parallels in Sweden
A significant amount of safer supply opioids are obviously being diverted to the black market, but some influential voices are vehemently downplaying this problem. They often claim that there are simply too few safer supply clients for diversion to be a real issue – but this argument is misleading because it glosses over the fact that these clients receive truly staggering amounts of narcotics relative to everyone else.
“Safer supply” refers to the practice of prescribing free recreational drugs as an alternative to potentially-tainted street substances. In Canada, that typically means distributing eight-mg tablets of hydromorphone, an opioid as potent as heroin, to mitigate the use of illicit fentanyl.
There is clear evidence that most safer supply clients regularly sell or trade almost all of their hydromorphone tablets for stronger illicit substances, and that this is flooding communities with the drug and fuelling new addictions and relapses. Just five years ago, the street price of an eight-mg hydromorphone tablet was around $20 in major Canadian cities – now they often go for as little as $1.
But advocates repeatedly emphasize that, even if such diversion is occurring, it must be a minor issue because there are only a few thousand safer supply clients in Canada. They believe that it is simply impossible for such a small population to have a meaningful impact on the overall black market for diverted pharmaceuticals, and that the sudden collapse of hydromorphone prices must have been caused by other factors.
This is an earnest belief – but an extremely ill-informed one.
It is difficult to analyze safer supply at the national level, as each province publishes different drug statistics that make interprovincial comparisons near-impossible. So, for the sake of clarity, let’s focus primarily on B.C., where the debate over safer supply has raged hottest.
According to a dashboard published by the British Columbia Centre for Disease Control, there were only 4,450 safer supply clients in the province in December 2023, of which 4,250 received opioids. In contrast, the 2018/19 British Columbia Controlled Prescription Drug Atlas (more recent data is unavailable) states that there were approximately 80,000 hydromorphone patients in the province that year – a number that is unlikely to have decreased significantly since then.
We can thus reasonably assume that safer supply clients represent around 5 per cent of the province’s total hydromorphone patients – but if so few people are on safer supply, how could they have a profound impact on the black market? The answer is simple: these clients receive astonishing sums of the drug, and divert at an unparalleled level, compared to everyone else.
Safer supply clients generally receive 4-8 eight-mg tablets per day at first, but almost all of them are quickly moved up to higher doses. In B.C., most patients are kept at 14 tablets (112-mg in total) per day, which is the maximum allowed by the province’s guidelines. For comparison, patients in Ontario can receive as many as 30 tablets a day (240-mg in total).
These are huge amounts.
The typical hydromorphone dose used to treat post-surgery pain in hospital settings is two-mg every 4-6 hours – or roughly 12-mg per day. So that means that safer supply clients can receive roughly 10-20 times the daily dose given to acute pain patients, depending on which province they’re located in. And while acute pain patients are tapered off hydromorphone after a few weeks, safer supply clients receive their tablets indefinitely.
Some chronic pain patients (i.e. people struggling with severe arthritis) are also prescribed hydromorphone – but, in most cases, their daily dose is 12-mg or less. The exception here is terminally ill cancer patients, who may receive up to around 100-mg of hydromorphone per day. However, this population is relatively small, so we once again have a situation where safer supply patients are, for the most part, receiving much more hydromorphone than their peers.
Not only do safer supply patients receive incredible amounts of the drug, they also seem to divert it at much higher rates – which is a frequently overlooked factor.
The clandestine nature of prescription drug diversion makes it near-impossible to measure, but a 2017 peer-reviewed study estimated that, in the United States, up to 3 per cent of all prescription opioids end up on the black market.
In contrast, it appears that safer supply patients divert 80-90 per cent of their hydromorphone.
These numbers should be taken with a grain of salt, as there have been no attempts to measure safer supply diversion – harm reduction researchers tend to simply ignore the problem, which means that we must rely on journalistic evidence that is necessarily anecdotal in nature. While this evidence has its limits, it can, at the very least, illustrate the rough scale of the problem.
For example, in London, Ontario, I interviewed six former drug users last summer who said that, of the safer supply clients they knew, 80 per cent sold almost all of their hydromorphone – just one interviewee placed the number closer to 50 per cent. More recently, I interviewed an addiction outreach worker in Ottawa who estimated that 90 per cent of safer supply clients diverted their drugs. These numbers are consistent with the testimony of dozens of addiction physicians who have said that safer supply diversion is ubiquitous.
Let us take a conservative estimate and imagine that only 30 per cent of safer supply hydromorphone is diverted – even this would be potentially catastrophic.
So we can see why any serious attempt to discuss safer supply diversion cannot narrowly focus on patient numbers – to ignore differences in doses and diversion rates is inexcusably misleading.
But we don’t need to rely on theory to make this point, because the recent parliamentary testimony of Fiona Wilson, who is deputy chief of the Vancouver Police Department and president of the B.C. Association of Chiefs of Police (BCACP), illustrates the situation quite neatly.
Wilson testified to the House of Commons health committee earlier this month that half of the hydromorphone recently seized in B.C. can be attributed to safer supply. As she did not specify whether the other half was attributed to other sources, or simply of indeterminate origin, the actual rate of safer supply hydromorphone seizures may actually be even higher.
As, once again, safer supply clients constitute roughly 5 per cent of the total hydromorphone patient population, Wilson’s testimony suggests that, on a per capita basis, safer supply patients divert at least 18 times more of the drug than everyone else.
This is exactly what one would expect to find given our earlier analysis, and these facts, by themselves, repudiate the argument that safer supply diversion is insignificant. When a small population is at least doubling the street supply of a dangerous pharmaceutical opioid, this is a problem.
The fact that so few people can cause substantial, system-wide harm is not unprecedented. In fact, this exact same problem was observed in Sweden, which, from 1965-1967, experimented with a model of safer supply that closely resembled what is being done in Canada today. A small number of patients – barely more than a hundred – were given near-unlimited access to free recreational drugs under the assumption that this would keep them “safe.”
But these patients simply sold the bulk of their drugs, which caused addiction and crime rates to skyrocket across Stockholm. Commentators at the time referred to safer supply as “the worst scandal in Swedish medical history,” and, even today, the experiment remains a cautionary tale among the country’s drug researchers.
It is simply wrong to say that there are too few safer supply clients to cause a diversion crisis. People who make this claim are ignorant of contemporary and historical facts, and those who wish to position themselves as drug experts should be mindful of this, lest they mislead the public about a destructive drug crisis.
This article was originally published in The Bureau, a Canadian publication devoted to using investigative journalism to tackle corruption and foreign influence campaigns. You can find this article on their website here.
Addictions
The Death We Manage, the Life We Forget
Marco Navarro-Génie
Our culture has lost the plot about what it means to live.
Reading that Manitoba is bringing supervised consumption to Winnipeg got me thinking.
Walk through just about any major Canadian city, and you will see them. Figures bent forward at seemingly impossible angles, swaying in the characteristic “fentanyl fold,” suspended between consciousness and oblivion. They resemble the zombies of fiction: bodies that move through space without agency, awareness, or connection to the world around them. We think of zombies as the walking dead. Health workers and bureaucrats reverse their overdoses, send them back to the street, and call it saving lives.
At the same time, Canada offers medical assistance in dying to a woman who cited chemical sensitivities and the inability to find housing. It has been offered to veterans who asked for support and were met instead with an option for death. We fight to prevent one form of death while facilitating another. The contradiction is not accidental. It reveals something about the people involved and the funding behind it. That’s our culture. Us. It appears to me that our culture no longer knows what life is.
Ask any politician or program bureaucrat, and you will hear them explain, in the dry language of bureaucracy, that the twin approach to what they call harm reduction and medical assistance in dying (MAiD) rests on the shared premise of what they believe to be compassion. They think they respect autonomy, prevent suffering, and keep people alive when possible. It sounds humane. It is, in practice, incoherent. Bear with me for a moment.
The medical establishment administers naloxone to reverse overdoses in people who spend as many as twenty hours a day unconscious. They live without meaningful relationships or memories, with little capacity for choice. The technocrats and politicians call that saving lives. They also provide assisted death to people whose suffering comes primarily from poverty, isolation, or lack of housing. There was a time when these factors could, at least in theory, be addressed so that the terminal decision did not need to be made. Now they are accepted as grounds for ending life.
But why is one preference final and the other treated as an error to correct? That question reflects the deeper disorientation.
We saw the same thing during COVID. Elderly people in care homes were left without touch, family, or comfort for days. They often died in solitude, their dementia accelerated by isolation. And those conditions were inflicted upon them in the name of saving their lives. The “system” measured success in preventing infections, not in preserving connections. Je me souviens. Or we should.
There is a pattern here. We have reduced the idea of saving lives to keeping bodies breathing, while ignoring what makes a life human: agency, meaning, development, and relationship. And in doing so, we begin to define life as mere biological persistence. But to define life by the capacity to breathe and perform basic functions is to place ourselves on the same footing as the non-human animals. It is to say, tacitly, that there is no fundamental distinction between a person and a creature. That, too, is a form of forgetting.
To be clear, the argument here is not that hopeless drug users should be administered MAiD. Instead, it is essential to recognize that the intellectual framework behind harm reduction and MAiD must be taken seriously, as it rests on some rationally defensible claims. In an age where most arguments are emotive and unexamined, the mildly logical has become strangely compelling.
It begins with the idea of autonomy. We cannot force others to live by our values. Every person must decide what makes life worth living. To insist otherwise is paternalism.
Then comes pragmatic compassion. People will use drugs whether we approve or not. People will find their lives unbearable, whether we acknowledge it or not. We can support them or moralize while they die.
There is also an emphasis on subjective experience. No one knows another’s pain. If someone says their suffering is intolerable, we are in no position to deny it, they say. If a user would rather face opioids than withdrawal and despair, are we entitled to interfere?
Finally, the comparison to medical ethics: we do not withhold insulin from diabetics who continue to eat poorly. We do not deny cancer treatment to smokers. Medicine responds to suffering, even when the patient has contributed to their condition. Harm reduction, they argue, simply applies that principle to addiction.
These arguments produced tangible benefits, they argue. Needle exchanges reduced HIV transmission. Naloxone kits prevented deaths. Safe injection sites meant fewer people dying alone. MAiD brought relief to those in agony. These were not trivial outcomes. I am aware.
Yet when we look more closely, the very logic that underlies these policies also exposes their fatal limitations.
Addiction undermines choice. It hijacks the brain’s ability to reason, compare, and choose. A person deep in addiction is not selecting between alternatives like someone choosing coffee or tea. The structure of choice, the human will, itself is broken. The addiction decides before the person does. St Augustine knew this. Dostoyevsky knew it too.
And for the empirically minded, the research supports this. In British Columbia, where the “safe supply” model was pioneered, some addiction physicians now say the policy is failing. Worse, it may be creating new opioid dependencies in people who were not previously addicted. A study earlier this year found that opioid‑related hospitalizations increased by about 33 percent, compared with pre‑policy rates. With the later addition of a drug-possession decriminalization policy, hospitalizations rose even more (overall, a 58 percent increase compared to before SOS’s implementation). The study concluded that neither safer supply nor decriminalization was associated with a statistically significant reduction in overdose deaths. This is not freedom. It is a new form of bondage, meticulously paved by official compassion.
Despair disguises itself as autonomy, especially in a spiritually unmoored culture that no longer knows how to cope with suffering. A person requesting assisted death because of chronic, untreatable pain may appear lucid and composed, but lucidity is not the same as wisdom. One can reason clearly from false premises. If life is reduced to the absence of pain and the preservation of comfort, then the presence of suffering will seem like failure, and death will appear rational. But that is not a genuine choice because it is based on a misapprehension of what life is. All life entails pain. Some of it is redemptive. Some of it is endured. But it does not follow that the presence of suffering justifies the conclusion of life.
Someone turning to drugs because of homelessness, abandonment, or despair is often in an even deeper eclipse of the will. Here, there is not even the appearance of deliberation, only the reach for numbness in the absence of meaning. What looks like a decision is the residue of collapse. We are not witnessing two forms of autonomy, one clearer than the other. We are witnessing the breakdown of autonomy in various forms, and pretending that it is freedom.
Biological survival is not life. When we maintain someone in a state of near-constant unconsciousness, with no relationships, no capacity for flourishing, we are not preserving life. We are preserving a body. The person may already be gone. To define life as nothing more than breathing and performing bodily functions is to deny what makes us human. It reduces us to the level of non-human creatures, sentient, perhaps, but without reason, memory, moral reflection, or the possibility of transcendence. It tacitly advances the view that there is no essential difference between a person and a critter, so long as both breathe and respond to some stimuli.
Governments do these things to keep ballooning overdosing deaths down, preferring to maintain drugs users among the undead instead. That reminds me of how the Mexican government hardly moves a finger to find the disappeared, 100,000 strong of lately. For as long ss they’re disappeared, they choose not to count them as homicides, and they feel justified in ignoring the causes of all the killing around them.
Some choices are nefarious. Some choices deserve challenge. Not all autonomous acts are equal. The decision to continue living with pain, or to fight addiction, requires agency. The decision to surrender to despair may signal the absence of it. To say all choices are equal is to empty the word autonomy of meaning.
This reflects a dangerously thin view of the human person that permeates our present. What we now call “harm” is only death or physical pain. What we call good is whatever someone prefers. But people are more than collections of wants.
We should have learned this by now. In Alberta, safer supply prescribing was effectively banned in 2022. Officials cited diversion and lack of measurable improvement. We are forcing some people into treatment because we recognize the impairment of judgement in addiction.
In British Columbia, public drug use was quietly re-criminalized after communities rebelled. This was an admission of policy failure. “Keeping people safe is our highest priority,” Premier David Eby said. Yet safe supply remains. In 2023, the province recorded more than 2,500 overdose deaths. Paramedics continue to respond to thousands of overdose calls each month. This is not success. It is a managed collapse.
Meanwhile, Manitoba is preparing to open its own supervised drug-use site. Premier Wab Kinew said, “We have too many Manitobans dying from overdose… so this is one tool we can use.” That may be so. However, it is a tool that others are beginning to set aside. It is a largely discredited tool. Sadly, in the self-professed age of “Reconciliation” with Aboriginal Canadians, Aboricompassionadians are disproportionately affected by these discredited policies.
The Manitoba example illustrates the broader problem, despite damning evidence. Instead of asking what helps people live, we ask whether they gave consent. We do not ask whether they were capable of it. We ask whether they avoided death. We do not ask whether they found purpose.
We are not asking what might lead someone out of addiction. We are not asking what they need to flourish. We ask only what we can do to prevent them from dying in the short term. And when that becomes impossible, technocracy offers them death in a more organized form, cleanly approved by government. That’s compasson.
The deeper problem is not policy incoherence. It is the cultural despair that skates on the thin ice of meaninglessness. These policies make sense only in a culture that has already decided life is not worth too much. What matters is state endorsement and how it’s done .
It is more cost-effective to distribute naloxone than to construct long-term recovery homes. It is easier to train nurses to supervise injection than to provide months of residential treatment. It is far simpler to legalize euthanasia for the poor and the suffering than to work on solutions that lift them out of both. But is it right?
This is not compassion. It is surrender.
A humane policy would aim to restore agency, not validate its absence. It would seek out what helps people grow in wisdom and self-command, not what leaves them comfortably sedated. It would measure success not in lives prolonged into darker dependency but in persons recovered. In lives better lived.
This vision is harder. It costs time. It requires greater effort. It requires care and what some Christians call love of neighbour. It may require saying no when someone asks for help that could lead to ruin. But anything less is not mercy. It is a slow walk toward death while we leave the “system” to pretend there is no choice.
We did have a choice. We chose shallow comfort over deep obligation. We chose to manage symptoms rather than confront the deeper conditions of our age: loneliness, meaninglessness, despair. And now we live among the results: more, not fewer, people swaying in silence, already gone walking dead.
We might ask what we’ve forgotten about suffering, about responsibility, about what life is. Lives are at stake. True. But when our understanding of life is misdirected, so will be the policies the state gives us.
We are grateful that you’re reading Haultain Research.
For the full experience, and to help us bring you more quality research and commentary,
Addictions
Activists Claim Dealers Can Fix Canada’s Drug Problem
By Adam Zivo
We should learn from misguided experiments with activist-driven drug ideologies.
Some Canadian public-health researchers have argued that the nation’s drug dealers, far from being a public scourge, are central to the cause of “harm reduction,” and that drug criminalization makes it harder for them to provide this much-needed “mutual aid.” Incredibly, these ideas have gained traction among Canada’s policymakers, and some have even been put into practice.
Gillian Kolla, an influential harm-reduction activist and researcher, spearheaded the push to whitewash drug trafficking in Canada. Over the past decade, she has advocated for many of the country’s failed laissez-faire drug policies. In her 2020 doctoral dissertation, she described her hands-on research into Toronto’s “harm reduction satellite sites”—government-funded programs that paid drug users to provide services out of their homes.
The sites Kolla studied were operated by the nonprofit South Riverdale Community Health Centre (SRCHC) in Toronto. Addicts participating in the programs received $250 per month in exchange for distributing naloxone and clean paraphernalia (needles and crack pipes, for example), as well as for reversing overdoses and educating acquaintances on safer consumption practices. At the time of Kolla’s research (2016–2017), the SRCHC was operating nine satellite sites, which reportedly distributed about 1,500 needles and syringes per month.
Canada permits supervised consumption sites—facilities where people can use drugs under staff oversight—to operate so long as they receive an official exemption via the federal Controlled Drugs and Substances Act. As the sites Kolla observed did not receive exemptions, they were certainly illegal. Kolla herself acknowledged this in her dissertation, writing that she, with the approval of the University of Toronto, never recorded real names or locations in her field notes, in case law enforcement subpoenaed her research data.
Even so, the program seems to have enjoyed the blessing of Toronto’s public health officials and police. The satellite sites received local funding from 2010 onward, after a decade of operating on a volunteer basis, apparently with special protection from law enforcement. In her dissertation, Kolla described how SRCHC staff trained police officers to leave their sites alone, and how satellite-site workers received special ID badges and plaques to ward off arrest.
Kolla made it clear that many of these workers were not just addicts but dealers, too, and that tolerance of drug trafficking was a “key feature” of the satellite sites. She even described, in detail, how she observed one of the site workers packaging and selling heroin alongside crackpipes and needles.
In her dissertation, Kolla advocated expanding this permissive approach. She claimed that traffickers practice harm reduction by procuring high-quality drugs for their customers and avoiding selling doses that are too strong.
“Negative framings of drug selling as predatory and inherently lacking in care make it difficult to perceive the wide variety of acts of mutual aid and care that surround drug buying and selling as practices of care,” she wrote.
In truth, dealers routinely sell customers tainted or overly potent drugs. Anyone who works in the addiction field can testify that this is a major reason that overdose deaths are so common.
Ultimately, Kolla argued that “real harm reduction” should involve drug traffickers, and that criminalization creates “tremendous barriers” to this goal.
The same year she published her dissertation, Kolla cowrote a paper in the Harm Reduction Journal with her Ph.D. supervisor at the Dalla Lana School of Public Health. The article affirmed the view that drug traffickers are essential to the harm-reduction movement. Around this time, the SRCHC collaborated with the Toronto-based Parkdale Queen West Community Health Centre— the only other organization running such sites—to produce guidelines on how to replicate and scale up the experiment.
Thankfully, despite its local adoption, this idea did not catch on at the national level. It was among the few areas in the early 2020s where Canada did not fully descend into addiction-enabling madness. Yet, like-minded researchers still echo Kolla’s work.
In 2024, for example, a group of American harm-reduction advocates published a paper in Drug and Alcohol Dependence Reports that concluded, based on just six interviews with drug traffickers in Indianapolis, that dealers are “uniquely positioned” to provide harm-reduction services, partly because they are motivated by “the moral imperative to provide mutual aid.” Among other things, the authors argued that drug criminalization is harmful because it removes dealers from their social networks and prevents them from enacting “community-based practices of ethics and care.”
It’s instructive to review what ultimately happened with the originators of this movement—Kolla and the SRCHC. Having failed to whitewash drug trafficking, Kolla moved on to advocating for “safer supply”—an experimental strategy that provides addicts with free recreational drugs to dissuade use of riskier street substances. The Canadian government funded and expanded safer supply, thanks in large part to Kolla’s academic work. It abandoned the experiment after news broke that addicts resell their safer supply on the black market to buy illicit fentanyl, flooding communities with diverted opioids and fueling addiction.
The SRCHC was similarly discredited after a young mother, Karolina Huebner-Makurat, was shot and killed near the organization’s supervised consumption site in 2023. Subsequent media reports revealed that the organization had effectively ignored community complaints about public safety, and that staff had welcomed, and even supported, drug traffickers. One of the SRCHC’s harm-reduction workers was eventually convicted of helping Huebner-Makurat’s shooter evade capture by hiding him from the police in an Airbnb apartment and lying to the police.
There is no need for policymakers to repeat these mistakes, or to embrace its dysfunctional, activist-driven drug ideologies. Let this be another case study of why harm-reduction policies should be treated with extreme skepticism.
Our content is always free
If you want to help us commission more high-quality journalism,
consider getting a voluntary paid subscription.
-
Alberta2 days agoFrom Underdog to Top Broodmare
-
Business2 days agoMan overboard as HMCS Carney lists to the right
-
Business2 days agoHigher carbon taxes in pipeline MOU are a bad deal for taxpayers
-
Alberta2 days agoREAD IT HERE – Canada-Alberta Memorandum of Understanding – From the Prime Minister’s Office
-
Daily Caller2 days agoZelenskyy Under Siege As Top Aide Resigns After Home Raided In Major Corruption Scandal
-
Alberta2 days agoIEA peak-oil reversal gives Alberta long-term leverage
-
Bruce Dowbiggin2 days agoHealthcare And Pipelines Are The Front Lines of Canada’s Struggle To Stay United
-
Alberta1 day agoAlberta can’t fix its deficits with oil money: Lennie Kaplan





